Ocriplasmin Intravitreal

Ocriplasmin Intravitreal is a prescription medication used for the treatment of symptomatic vitreomacular adhesion. 

• Ocriplasmin Intravitreal is available under the following different brand names: Jetrea.

Common side effects of Ocriplasmin Intravitreal include:

• Dry eyes

Serious side effects of Ocriplasmin Intravitreal include:

• Hives,
• Difficulty breathing,
• Swelling of the face, lips, tongue, or throat,
• Eye pain or redness,
• Vision changes,
• Yellowish vision, and
• Increased sensitivity to light

Rare side effects of Ocriplasmin Intravitreal include:

• none 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, coordination loss, unsteady, very stiff muscles, high fever, profuse sweating, or tremors.
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights.
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Intravitreal solution

• 0.125 mg/0.1 mL (0.375 mg/0.3 mL)
• Note: Solution reformulated as of February 2017; reformulated solution does NOT require further dilution

Vitreomacular Adhesion

Adult dosage

• 0.125 mg (0.1 mL) by Intravitreal injection to the affected eye once as a single injection

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Ocriplasmin Intravitreal has no noted severe interactions with any other drugs.
• Ocriplasmin Intravitreal has no noted serious interactions with any other drugs.
• Ocriplasmin Intravitreal has no noted moderate interactions with any other drugs.
• Ocriplasmin Intravitreal has no noted minor interactions with any other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice or health questions or concerns.

Contraindications

• None

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Ocriplasmin Intravitreal?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Ocriplasmin Intravitreal?”

Cautions

• Decrease of 3-lines or more BCVA; these decreases in vision were due to the progression of the condition and many required surgical interventions
• Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage, and increased IOP
• Potential for lens subluxation
• Retinal breaks (e.g., detachment, tear) reported
• Dyschromatopsia (yellowish vision) and electroretinographic changes (a- and b-wave amplitude decreases) were reported

Pregnancy and Lactation

• Use with caution if the benefits outweigh the risks during pregnancy
• Lactation
  • Unknown whether distributed in breast milk; caution advised